NASDAQ:FULC Fulcrum Therapeutics (FULC) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free FULC Stock Alerts $7.91 +0.56 (+7.62%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$7.41▼$8.5050-Day Range$6.84▼$12.0052-Week Range$2.65▼$13.70Volume1.11 million shsAverage Volume622,445 shsMarket Capitalization$491.61 millionP/E RatioN/ADividend YieldN/APrice Target$14.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Fulcrum Therapeutics alerts: Email Address Fulcrum Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside81.2% Upside$14.33 Price TargetShort InterestBearish4.83% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 20 Articles This WeekInsider TradingSelling Shares$59,072 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.76) to ($1.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.10 out of 5 starsMedical Sector1755th out of 2,771 stocksPharmaceutical Preparations Industry824th out of 1,288 stocks 4.5 Analyst's Opinion Consensus RatingFulcrum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFulcrum Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Fulcrum Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.83% of the outstanding shares of Fulcrum Therapeutics have been sold short.Short Interest Ratio / Days to CoverFulcrum Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Fulcrum Therapeutics has recently increased by 18.58%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldFulcrum Therapeutics does not currently pay a dividend.Dividend GrowthFulcrum Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FULC. Previous Next 1.8 News and Social Media Coverage News SentimentFulcrum Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Fulcrum Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for FULC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,072.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Fulcrum Therapeutics is held by insiders.Percentage Held by Institutions89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulcrum Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fulcrum Therapeutics are expected to grow in the coming year, from ($1.76) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulcrum Therapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulcrum Therapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulcrum Therapeutics has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Fulcrum Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden FINISHED On June 13th?Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered.Click here now to see his shocking evidence. About Fulcrum Therapeutics Stock (NASDAQ:FULC)Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More FULC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FULC Stock News HeadlinesMay 14 at 7:09 PM | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)May 14 at 7:09 PM | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2024 Earnings Call TranscriptMay 14 at 8:47 AM | finance.yahoo.comWill Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?May 14 at 3:47 AM | finance.yahoo.comFulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 13 at 9:57 AM | markets.businessinsider.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024May 13 at 9:57 AM | finance.yahoo.comFulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...May 13 at 7:00 AM | globenewswire.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024May 13 at 6:00 AM | globenewswire.comFulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular DystrophyMay 12 at 6:56 PM | markets.businessinsider.comHere's what to expect from Fulcrum Therapeutics's earningsMay 11 at 1:44 AM | americanbankingnews.comFulcrum Therapeutics (FULC) Scheduled to Post Quarterly Earnings on MondayMay 9, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate in Upcoming May ConferencesMay 8, 2024 | finance.yahoo.comFulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet NeurologyMay 6, 2024 | globenewswire.comFulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ETMay 4, 2024 | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 1, 2024 | finance.yahoo.comEpsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company ExpansionApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialMarch 28, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy SymposiumMarch 22, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 19, 2024 | finance.yahoo.comFULC Apr 2024 9.000 putMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)March 18, 2024 | finanznachrichten.deFulcrum Therapeutics, Inc.: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerMarch 18, 2024 | msn.comFulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical OfficerMarch 18, 2024 | globenewswire.comFulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerMarch 13, 2024 | tmcnet.comFulcrum Deepens Collaboration with Esri, Recognized as Bronze PartnerMarch 8, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive FULC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/14/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FULC CUSIPN/A CIK1680581 Webwww.fulcrumtx.com Phone(617) 651-8851FaxN/AEmployees76Year FoundedN/APrice Target and Rating Average Stock Price Target$14.33 High Stock Price Target$17.00 Low Stock Price Target$11.00 Potential Upside/Downside+88.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,330,000.00 Net Margins-3,470.05% Pretax Margin-3,470.05% Return on Equity-36.65% Return on Assets-33.62% Debt Debt-to-Equity RatioN/A Current Ratio17.71 Quick Ratio17.71 Sales & Book Value Annual Sales$2.81 million Price / Sales172.52 Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book2.05Miscellaneous Outstanding Shares62,150,000Free Float59,606,000Market Cap$484.77 million OptionableOptionable Beta2.35 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Alexander C. Sapir (Age 57)CEO, President & Director Dr. Bradley E. Bernstein M.D.Ph.D., FounderDr. Michael R. GreenFounderDr. Rudolf Jaenisch M.D.Ph.D., FounderDr. Tsun-Huei Lee M.D. (Age 60)Ph.D., Founder Dr. Danny ReinbergFounderMr. Alan A. Musso C.M.A. (Age 62)CPA, Chief Financial Officer Mr. Gregory TourangeauController & Principal Accounting OfficerDr. Jeffrey W. Jacobs Ph.D. (Age 61)Chief Scientific Officer Mr. Curtis G. Oltmans J.D. (Age 61)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $83.98kMore ExecutivesKey CompetitorsEntrada TherapeuticsNASDAQ:TRDATheravance BiopharmaNASDAQ:TBPHAcelyrinNASDAQ:SLRNRevance TherapeuticsNASDAQ:RVNCPepGenNASDAQ:PEPGView All CompetitorsInsiders & InstitutionsStemPoint Capital LPBought 30,535 shares on 5/14/2024Ownership: 0.655%Vanguard Group Inc.Bought 18,681 shares on 5/10/2024Ownership: 4.084%SG Americas Securities LLCBought 12,206 shares on 5/7/2024Ownership: 0.020%Greg TourangeauSold 236 sharesTotal: $1,831.36 ($7.76/share)Marquette Asset Management LLCSold 21,828 shares on 5/7/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions FULC Stock Analysis - Frequently Asked Questions Should I buy or sell Fulcrum Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FULC shares. View FULC analyst ratings or view top-rated stocks. What is Fulcrum Therapeutics' stock price target for 2024? 6 brokerages have issued 1 year price objectives for Fulcrum Therapeutics' shares. Their FULC share price targets range from $11.00 to $17.00. On average, they predict the company's share price to reach $14.33 in the next twelve months. This suggests a possible upside of 81.2% from the stock's current price. View analysts price targets for FULC or view top-rated stocks among Wall Street analysts. How have FULC shares performed in 2024? Fulcrum Therapeutics' stock was trading at $6.75 at the beginning of 2024. Since then, FULC stock has increased by 17.2% and is now trading at $7.91. View the best growth stocks for 2024 here. When is Fulcrum Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our FULC earnings forecast. How were Fulcrum Therapeutics' earnings last quarter? Fulcrum Therapeutics, Inc. (NASDAQ:FULC) announced its earnings results on Tuesday, February, 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.04. The company earned $0.87 million during the quarter, compared to the consensus estimate of $0.65 million. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative trailing twelve-month return on equity of 36.65%. What ETFs hold Fulcrum Therapeutics' stock? ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Simplify Health Care ETF (PINK), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What other stocks do shareholders of Fulcrum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO). When did Fulcrum Therapeutics IPO? Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering on Thursday, July 18th 2019. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO. Who are Fulcrum Therapeutics' major shareholders? Fulcrum Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.08%), StemPoint Capital LP (0.66%), Mass General Brigham Inc (0.33%), Commonwealth Equity Services LLC (0.13%), Mirae Asset Global Investments Co. Ltd. (0.05%) and Denali Advisors LLC (0.04%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Greg Tourangeau, James A Geraghty, Peter G Thomson, Ra Capital Management, LP, Robert J Gould and Robert J Gould. View institutional ownership trends. How do I buy shares of Fulcrum Therapeutics? Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FULC) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsAmerica’s worst nightmare?Porter & CompanyCrypto Millionaire Says: “Buy This $11 AI Coin.”InvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.